Conditional Cytotoxic Anti-HIV Gene Therapy for Selectable Cell Modification

Selectable Markers for Gene Therapy

One of the major problems with current approaches to gene 9 therapy is the instability of expression of genes transferred into 10 recipient cells. Although in theory, homologous recombination 11 or use of artificial chromosomes can stabilize sequences with 12 wild-type regulatory regions, such approaches to gene therapy 13 are not yet feasible and may not be efficient for some time to 14 come. ...

Development of HIV vectors for anti-HIV gene therapy.

Current gene therapy protocols for HIV infection use transfection or murine retrovirus mediated transfer of antiviral genes into CD4+ T cells or CD34+ progenitor cells ex vivo, followed by infusion of the gene altered cells into autologous or syngeneic/allogeneic recipients. While these studies are essential for safety and feasibility testing, several limitations remain: long-term reconstitutio...

Cell-Delivered Gene Therapy for HIV

SLCO2B1 gene polymorphism and anti-retroviral therapy side effects in HIV-1 infected patients

Abstract Background and Objectives HIV virus and its subsequent disease is one of the most important challenges of the world health system. Although antiretroviral therapy (ART) is a breakthrough in patients’ life quality, it has complications like side effects. The side effect causes are diverse. One of the factors considered about side effects is genes polymorphism. This study investigates th...

Conditional gene targeting for cancer gene therapy.

Current treatment of solid tumors is limited by severe adverse effects, resulting in a narrow therapeutic index. Therefore, cancer gene therapy has emerged as a targeted approach that would significantly reduce undesired side effects in normal tissues. This approach requires a clear understanding of the molecular biology of both the malignant clone and the biological vectors that serve as vehic...